Jeffrey Dierks
Senior Director, U.S. Migraine Marketing
Teva Pharmaceuticals
Patient-Centric Pain Portfolio Producer
Jeffrey Dierks’ numerous years of marketing experience includes time dedicated to Pain Care, Migraine, Psychiatry, Women’s Healthcare, Urology, and Dermatology—just to name a few. His exceptional leadership, impact on the healthcare community, and passion for patients has been recognized several times throughout his career, including winning the American Academy of Dermatology Golden Triangle Award for the “Play Safe in the Sun” Skin Cancer Awareness Campaign and the National Headache Foundation “Partners in Excellence Award” for the Menstrual Migraine Awareness Campaign. But Jeff may have done some of his best work over the last year growing and managing a dynamic pain care portfolio of products.
While overseeing Teva Pharmaceuticals’ U.S. Pain Care Marketing portfolio of brands, Jeff was tasked with overseeing 11 assets in different phases of their lifecycle—two investigational abuse-deterrent opioids in development, one abuse-deterrent opioid NDA under review by the FDA, two mature brands, one product approaching the end of its lifecycle/loss of exclusivity, and four non-promoted brands post-LOE competing with numerous generics. Jeff demonstrated his ability to adapt for each product’s needs, leveraging insights and his marketing discipline to deliver impact for each brand. Together, he and his team executed on the brand strategic plan to achieve the brand financial targets and most importantly, kept patients at the center of everything they did.
His work on the pain portfolio brought in $450 million in net sales in 2016—a 99% achievement of the business goal, which is noteworthy in that a portion of the team’s sales goals included the forecast for the not-yet-approved investigational abuse-deterrent opioid that didn’t achieve FDA approval until 2017.
Jeff also kept true to his patient-centric core by identifying a need in advancing education in the highly charged opioid space—the development, growth, and evolution of Teva’s Pain Matters unbranded educational initiative. Pain Matters targets the pain care community (patients, caregivers, HCPs, and advocacy) focused on responsible pain management and the role of abuse deterrent opioids. Pain Matters impact has already been recognized with industry awards demonstrating the value it has brought to the pain care community.
